Clinical trials: Carcinoid
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg)…
- Trial name
- NETTER-1 (NCT01578239)
- Testing
- Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 231 people
- Sponsor
- Advanced Accelerator Applications
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1
- Trial name
- NCT03375320
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 432 sites in United States
- Volunteers
- 298 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Carcinoid Tumor, Metastatic Carcinoid Tumor
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary…
- Conditions
- Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm
- Trial name
- NCT02399215
- Testing
- Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Roswell Park Cancer Institute
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Islet Cell Carcinoma, Neuroendocrine Carcinoma
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy.
- Conditions
- Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
- Trial name
- NCT00363051
- Testing
- Everolimus 10 mg, Octreotide Depot
- Where
- 54 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Carcinoma
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
The primary purpose of the study is to investigate the effects of high-dose octreotide on flushing, diarrhea, and quality of life in patients whose disease-related symptoms are inadequately controlled by the maximum approved dose…
- Trial name
- NCT01886287
- Testing
- Octreotide LAR
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Symptomatic Refractory Resistant Carcinoid Disease
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available…
- Trial name
- NCT00690430
- Testing
- Pasireotide, Octreotide
- Where
- 62 sites in United States, Argentina and 14 more
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Syndrome
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of…
- Trial name
- CAMPANULA (NCT01018953)
- Testing
- BIM 23A760
- Where
- 54 sites in Austria, Belgium and 16 more
- Volunteers
- 8 people
- Sponsor
- Ipsen
Carcinoid Tumors
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
- Trial name
- NCT02795858
- Testing
- Ramucirumab, Somatostatin Analog
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to…
- Trial name
- NCT04810091
- Testing
- Questionnaire Administration, Telotristat Ethyl
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoid Syndrome
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
- Trial name
- TELEPATH (NCT02026063)
- Testing
- Telotristat etiprate
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 124 people
- Sponsor
- Lexicon Pharmaceuticals
Zollinger-Ellison Syndrome
YF476 and Type II Gastric Carcinoids
This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison…
- Trial name
- NCT02454075
- Testing
- YF476
- Volunteers
- 3 people
- Sponsor
- Trio Medicines Ltd.
Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
- Trial name
- NCT00088595
- Testing
- Pasireotide (SOM230)
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs)
- Trial name
- RAMSETE/CDE16 (NCT00688623)
- Testing
- Everolimus
- Where
- 40 sites in France, Germany and 6 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals